Cumberland Pharmaceu (CPIX)

$7.77 +0.59 (8.22%)
Market Cap 100.09M
Revenue (ttm) 44.52M
Net Income (ttm) -2.84M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -6.38%
Debt to Equity Ratio 0.25
Volume 200,256
Avg Vol 105,362
Day's Range N/A - N/A
Shares Out 14.98M
Stochastic %K 69%
Beta 0.09
Analysts Strong Buy
Price Target $8.50

Company Profile

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso, a transdermal patch for the prevention of nausea and vomiting in patients receiving chemotherapy tr...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 615 255 0068
Fax: 615 255 0094
Address:
1600 West End Avenue, Suite 1300, Nashville, United States
TooHot_toTouch
TooHot_toTouch Aug. 4 at 6:34 PM
$CADL I think there are a few very good options for companies approaching the patent cliff. I would count all 3 in the mix to attract interests. $SLS $CPIX
2 · Reply
haha1978
haha1978 Aug. 4 at 5:29 PM
$CPIX could be any of these 3 companies. We don't really know.
0 · Reply
haha1978
haha1978 Aug. 4 at 5:21 PM
$CPIX and $CADL
1 · Reply
TwinTurboBul161
TwinTurboBul161 Aug. 4 at 3:51 PM
$XGN $CPIX Jet102
3 · Reply
KUMO2026
KUMO2026 Aug. 4 at 1:58 PM
$CPIX 8.06 test on the monthly
1 · Reply
KUMO2026
KUMO2026 Aug. 4 at 1:57 PM
$CPIX swing trade into break out
0 · Reply
TwinTurboBul161
TwinTurboBul161 Aug. 4 at 9:05 AM
$EZRA $GSUN $CPIX /watching3
0 · Reply
haha1978
haha1978 Aug. 4 at 5:09 AM
$CPIX tomorrow will be real interesting. Hoping the stock rerates on Wednesday to normal valuations a 300 million market cap so more institutions can start loading. This shpuld eventually be $20 minimum equal to capr at a minimum. They spiked to 700 plus million market cap on green light for AA on DMD cardiomyopathy by peter marks. So if cpic got a green light like capr on their p2. Boom probably 40 to 50 dollars a share by comparison. Its a great example of whst could happen.
0 · Reply
haha1978
haha1978 Aug. 4 at 2:38 AM
$CPIX still could be a cancer partnership soon.
0 · Reply
integrityfirst
integrityfirst Aug. 3 at 11:27 PM
$CPIX what matters right now, is the DMD extended study data. We hopefully will learn tomorrow when and how the data is to be delivered. Hopefully a Scientific conference or publication. If not that, there are other effective means of delivering. Ideally the company at least identifies date/context. Certainly tomorrow we should learn more of the current state of company post sale. We remain bullish on DMD as an indication. Further we are encouraged by the Phase 2A Cancer Metastatis trial data and think that this drug, in that indication, is already meaningfully partnered or sold. There is lots to discuss about this company's current state. Perhaps I will wait till after tomorrow's earnings call to opine/project. We are bullish.
0 · Reply
Latest News on CPIX
CUMBERLAND PHARMACEUTICALS REPORTS COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS

Aug 4, 2026, 5:06 PM EDT - 5 minutes ago

CUMBERLAND PHARMACEUTICALS REPORTS COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS

Jul 28, 2026, 4:05 PM EDT - 7 days ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS

Cumberland announces special dividend of $1.50 per share

2026-07-13T14:55:32.000Z - 22 days ago

Cumberland announces special dividend of $1.50 per share

Cumberland board authorizes $5M share repurchase program

2026-07-13T14:55:27.000Z - 22 days ago

Cumberland board authorizes $5M share repurchase program

CUMBERLAND PHARMACEUTICALS ANNOUNCES SPECIAL DIVIDEND OF $1.50 PER SHARE

Jul 13, 2026, 10:46 AM EDT - 22 days ago

CUMBERLAND PHARMACEUTICALS ANNOUNCES SPECIAL DIVIDEND OF $1.50 PER SHARE

Apotex Completes Previously Announced Strategic Transaction with Cumberland Pharmaceuticals

Jul 1, 2026, 9:00 AM EDT - 4 weeks ago

Apotex Completes Previously Announced Strategic Transaction with Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Closes Strategic Transaction with Apotex

Jul 1, 2026, 9:00 AM EDT - 4 weeks ago

Cumberland Pharmaceuticals Closes Strategic Transaction with Apotex

Cumberland shares updated FIGHT DMD trial results

2026-06-26T15:05:14.000Z - 5 weeks ago

Cumberland shares updated FIGHT DMD trial results

Cumberland Pharmaceuticals Shares Updated FIGHT DMD Trial Results at the Parent Project Muscular Dystrophy Annual Conference

Jun 26, 2026, 11:00 AM EDT - 5 weeks ago

Cumberland Pharmaceuticals Shares Updated FIGHT DMD Trial Results at the Parent Project Muscular Dystrophy Annual Conference

RedHill Biopharma Announces Closing of Up To $19.4 Million Private Placement

Jun 22, 2026, 4:10 PM EDT - 6 weeks ago

RedHill Biopharma Announces Closing of Up To $19.4 Million Private Placement

RDHL

RedHill Biopharma Announces Up To $19.4 Million Private Placement

Jun 18, 2026, 8:00 AM EDT - 6 weeks ago

RedHill Biopharma Announces Up To $19.4 Million Private Placement

RDHL

RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation

Jun 9, 2026, 7:00 AM EDT - 2 months ago

RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation

RDHL

RedHill Launches Enforcement of $11 Million New York Supreme Court Final Judgment Against Kukbo

Jun 8, 2026, 7:00 AM EDT - 2 months ago

RedHill Launches Enforcement of $11 Million New York Supreme Court Final Judgment Against Kukbo

RDHL

Cumberland announces data from Phase 2a clinical trial of ifetroban

2026-06-02T14:45:10.000Z - 2 months ago

Cumberland announces data from Phase 2a clinical trial of ifetroban

Cumberland Pharmaceuticals and Vanderbilt Health Announce Potential New Therapy to Prevent Cancer Metastasis

Jun 2, 2026, 9:05 AM EDT - 2 months ago

Cumberland Pharmaceuticals and Vanderbilt Health Announce Potential New Therapy to Prevent Cancer Metastasis

RedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense Platforms

Jun 2, 2026, 8:00 AM EDT - 2 months ago

RedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense Platforms

RDHL

Cumberland announces launch of Vibativ in China

2026-05-28T14:51:26.000Z - 2 months ago

Cumberland announces launch of Vibativ in China

CUMBERLAND PHARMACEUTICALS ANNOUNCES LAUNCH OF VIBATIV® IN CHINA

May 28, 2026, 9:05 AM EDT - 2 months ago

CUMBERLAND PHARMACEUTICALS ANNOUNCES LAUNCH OF VIBATIV® IN CHINA

Cumberland Pharmaceuticals Proxy statement: Proxy filing

May 26, 2026, 8:00 AM EDT - 2 months ago

Cumberland Pharmaceuticals Proxy statement: Proxy filing

Cumberland Pharmaceuticals Proxy statement: Proxy filing

May 15, 2026, 8:00 AM EDT - 2 months ago

Cumberland Pharmaceuticals Proxy statement: Proxy filing

CUMBERLAND PHARMACEUTICALS REPORTS Q1 2026 FINANCIAL RESULTS & COMPANY UPDATE

May 5, 2026, 5:00 PM EDT - 3 months ago

CUMBERLAND PHARMACEUTICALS REPORTS Q1 2026 FINANCIAL RESULTS & COMPANY UPDATE

Cumberland Pharmaceuticals Earnings Call Transcript: Q1 2026

May 5, 2026, 4:30 PM EDT - 3 months ago

Cumberland Pharmaceuticals Earnings Call Transcript: Q1 2026

Cumberland Pharmaceuticals Earnings release: Q1 2026

May 5, 2026, 4:30 PM EDT - 3 months ago

Cumberland Pharmaceuticals Earnings release: Q1 2026

Cumberland Pharmaceuticals Quarterly report: Q1 2026

May 5, 2026, 4:30 PM EDT - 3 months ago

Cumberland Pharmaceuticals Quarterly report: Q1 2026

RedHill's RHB-204 Demonstrates Comparable MAP Killing Efficacy to RHB-104 - Important Step in RHB-204 Development for MAP-related Crohn's Disease

Apr 30, 2026, 7:00 AM EDT - 3 months ago

RedHill's RHB-204 Demonstrates Comparable MAP Killing Efficacy to RHB-104 - Important Step in RHB-204 Development for MAP-related Crohn's Disease

RDHL

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q1 2026 FINANCIAL RESULTS & COMPANY UPDATE

Apr 28, 2026, 4:05 PM EDT - 3 months ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q1 2026 FINANCIAL RESULTS & COMPANY UPDATE

RedHill Biopharma Announces Full-Year 2025 Financial Results and Operational Highlights

Apr 27, 2026, 8:00 AM EDT - 3 months ago

RedHill Biopharma Announces Full-Year 2025 Financial Results and Operational Highlights

RDHL

Cumberland announces transaction to integrate commercial business with Apotex

2026-04-23T13:13:38.000Z - 3 months ago

Cumberland announces transaction to integrate commercial business with Apotex

Cumberland Pharmaceuticals Announces Strategic Transaction to Integrate Commercial Business with Apotex

Apr 23, 2026, 9:00 AM EDT - 3 months ago

Cumberland Pharmaceuticals Announces Strategic Transaction to Integrate Commercial Business with Apotex

Cumberland Pharmaceuticals Proxy statement: Proxy filing

Apr 23, 2026, 8:00 AM EDT - 3 months ago

Cumberland Pharmaceuticals Proxy statement: Proxy filing

RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026

Apr 22, 2026, 8:00 AM EDT - 3 months ago

RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026

RDHL

Cumberland receives FDA approval for expanded Caldolor injection

2026-04-16T13:58:04.000Z - 3 months ago

Cumberland receives FDA approval for expanded Caldolor injection

CUMBERLAND PHARMACEUTICALS ANNOUNCES EXPANDED INDICATION FOR CALDOLOR® (IBUPROFEN) INJECTION AND LAUNCH OF NEW BRAND WEBSITE

Apr 16, 2026, 9:05 AM EDT - 3 months ago

CUMBERLAND PHARMACEUTICALS ANNOUNCES EXPANDED INDICATION FOR CALDOLOR® (IBUPROFEN) INJECTION AND LAUNCH OF NEW BRAND WEBSITE

Cumberland announces launch of new Sancuso website

2026-03-17T13:21:41.000Z - 5 months ago

Cumberland announces launch of new Sancuso website

Cumberland Pharmaceuticals Launches New Sancuso® Website Featuring Educational Resources for Chemotherapy-Induced Nausea and Vomiting

Mar 17, 2026, 9:05 AM EDT - 5 months ago

Cumberland Pharmaceuticals Launches New Sancuso® Website Featuring Educational Resources for Chemotherapy-Induced Nausea and Vomiting

Cumberland Pharmaceuticals Proxy statement: Proxy Filing

Mar 9, 2026, 8:00 AM EDT - 5 months ago

Cumberland Pharmaceuticals Proxy statement: Proxy Filing

Cumberland Pharmaceuticals Proxy statement: Proxy Filing

Mar 9, 2026, 8:00 AM EDT - 5 months ago

Cumberland Pharmaceuticals Proxy statement: Proxy Filing

CUMBERLAND PHARMACEUTICALS REPORTS 31% FOURTH QUARTER 2025 REVENUE GROWTH

Mar 3, 2026, 5:00 PM EST - 5 months ago

CUMBERLAND PHARMACEUTICALS REPORTS 31% FOURTH QUARTER 2025 REVENUE GROWTH

Cumberland Pharmaceuticals Earnings Call Transcript: Q4 2025

Mar 3, 2026, 4:30 PM EST - 5 months ago

Cumberland Pharmaceuticals Earnings Call Transcript: Q4 2025

Cumberland Pharmaceuticals Annual report: Q4 2025

Mar 3, 2026, 4:30 PM EST - 5 months ago

Cumberland Pharmaceuticals Annual report: Q4 2025

Cumberland Pharmaceuticals Earnings release: Q4 2025

Mar 3, 2026, 4:30 PM EST - 5 months ago

Cumberland Pharmaceuticals Earnings release: Q4 2025

Cumberland Pharmaceuticals Annual report: Q4 2025

Mar 3, 2026, 4:30 PM EST - 5 months ago

Cumberland Pharmaceuticals Annual report: Q4 2025

Cumberland and THI announce U.S. commercialization of Talicia

2026-02-25T12:20:11.000Z - 5 months ago

Cumberland and THI announce U.S. commercialization of Talicia

RedHill Biopharma announces full sales and operational launch of Talicia

2026-02-25T12:17:19.000Z - 5 months ago

RedHill Biopharma announces full sales and operational launch of Talicia

RDHL

Joint U.S. Commercialization of RedHill's Talicia® Commences

Feb 25, 2026, 7:00 AM EST - 5 months ago

Joint U.S. Commercialization of RedHill's Talicia® Commences

RDHL

CUMBERLAND PHARMACEUTICALS LAUNCHES U.S. PROMOTION OF TALICIA®

Feb 25, 2026, 7:00 AM EST - 5 months ago

CUMBERLAND PHARMACEUTICALS LAUNCHES U.S. PROMOTION OF TALICIA®

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE 2025 ANNUAL FINANCIAL RESULTS & COMPANY UPDATE

Feb 24, 2026, 4:05 PM EST - 5 months ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE 2025 ANNUAL FINANCIAL RESULTS & COMPANY UPDATE

Cumberland receives fast track designation for DMD oral therapy from FDA

2026-02-04T14:11:54.000Z - 6 months ago

Cumberland receives fast track designation for DMD oral therapy from FDA

Cumberland Pharmaceuticals Receives FDA Fast Track Designation for its Ifetroban Duchenne Muscular Dystrophy Program

Feb 4, 2026, 9:05 AM EST - 6 months ago

Cumberland Pharmaceuticals Receives FDA Fast Track Designation for its Ifetroban Duchenne Muscular Dystrophy Program

CALDOLOR® (IBUPROFEN) INJECTION CMS ISSUED J-CODE NOW ASSOCIATED WITH REIMBURSEMENT PRICE SUPPORTING NON-OPIOID PAIN MANAGEMENT

Dec 8, 2025, 9:05 AM EST - 8 months ago

CALDOLOR® (IBUPROFEN) INJECTION CMS ISSUED J-CODE NOW ASSOCIATED WITH REIMBURSEMENT PRICE SUPPORTING NON-OPIOID PAIN MANAGEMENT

CUMBERLAND PHARMACEUTICALS REPORTS 12% YEAR-TO-DATE REVENUE GROWTH

Nov 4, 2025, 5:00 PM EST - 9 months ago

CUMBERLAND PHARMACEUTICALS REPORTS 12% YEAR-TO-DATE REVENUE GROWTH

Cumberland Pharmaceuticals Earnings Call Transcript: Q3 2025

Nov 4, 2025, 4:30 PM EST - 9 months ago

Cumberland Pharmaceuticals Earnings Call Transcript: Q3 2025

Cumberland Pharmaceuticals Quarterly report: Q3 2025

Nov 4, 2025, 4:30 PM EST - 9 months ago

Cumberland Pharmaceuticals Quarterly report: Q3 2025

Cumberland Pharmaceuticals Earnings release: Q3 2025

Nov 4, 2025, 4:30 PM EST - 9 months ago

Cumberland Pharmaceuticals Earnings release: Q3 2025

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q3 2025 FINANCIAL RESULTS & COMPANY UPDATE

Oct 28, 2025, 4:05 PM EDT - 10 months ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q3 2025 FINANCIAL RESULTS & COMPANY UPDATE

RedHill Biopharma signs strategic partnership with Cumberland

2025-10-20T13:05:16.000Z - 10 months ago

RedHill Biopharma signs strategic partnership with Cumberland

RDHL

CUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIO

Oct 20, 2025, 9:05 AM EDT - 10 months ago

CUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIO

RDHL

RedHill's Talicia® Secures $4 Million Strategic Investment and U.S. Co-Commercialization Partnership Deal

Oct 20, 2025, 9:00 AM EDT - 10 months ago

RedHill's Talicia® Secures $4 Million Strategic Investment and U.S. Co-Commercialization Partnership Deal

Cumberland adds Vibativ to national group purchasing agreement with Premier

2025-10-13T13:10:36.000Z - 10 months ago

Cumberland adds Vibativ to national group purchasing agreement with Premier

CUMBERLAND PHARMACEUTICALS' VIBATIV® ADDED TO NATIONAL GROUP PURCHASING AGREEMENT WITH PREMIER, INC.

Oct 13, 2025, 9:05 AM EDT - 10 months ago

CUMBERLAND PHARMACEUTICALS' VIBATIV® ADDED TO NATIONAL GROUP PURCHASING AGREEMENT WITH PREMIER, INC.

Cumberland says ibuprofen injection product gets regulatory approval in Mexico

2025-10-01T13:10:20.000Z - 10 months ago

Cumberland says ibuprofen injection product gets regulatory approval in Mexico

CUMBERLAND PHARMACEUTICALS ANNOUNCES PRODUCT APPROVAL IN MEXICO

Oct 1, 2025, 9:05 AM EDT - 10 months ago

CUMBERLAND PHARMACEUTICALS ANNOUNCES PRODUCT APPROVAL IN MEXICO

Cumberland announces launch of Vibativ injection in Saudi Arabia

2025-09-29T13:10:14.000Z - 11 months ago

Cumberland announces launch of Vibativ injection in Saudi Arabia

TABUK LAUNCHES VIBATIV® FDA-APPROVED ANTIBIOTIC WITH LIFE-SAVING POTENTIAL IN SAUDI ARABIA

Sep 29, 2025, 9:05 AM EDT - 11 months ago

TABUK LAUNCHES VIBATIV® FDA-APPROVED ANTIBIOTIC WITH LIFE-SAVING POTENTIAL IN SAUDI ARABIA

Cumberland Pharmaceuticals Earnings Call Transcript: Q2 2025

Aug 5, 2025, 4:30 PM EDT - 1 year ago

Cumberland Pharmaceuticals Earnings Call Transcript: Q2 2025

Cumberland Pharmaceuticals Quarterly report: Q2 2025

Aug 5, 2025, 4:30 PM EDT - 1 year ago

Cumberland Pharmaceuticals Quarterly report: Q2 2025

Cumberland Pharmaceuticals Earnings release: Q2 2025

Aug 5, 2025, 4:30 PM EDT - 1 year ago

Cumberland Pharmaceuticals Earnings release: Q2 2025

Cumberland Pharmaceuticals Reports 23% Revenue Growth Year-to-Date

Aug 5, 2025, 4:05 PM EDT - 1 year ago

Cumberland Pharmaceuticals Reports 23% Revenue Growth Year-to-Date

Cumberland announces availability of Vibativo 4-Vial Starter Pak through Vizient

2025-08-04T13:10:32.000Z - 1 year ago

Cumberland announces availability of Vibativo 4-Vial Starter Pak through Vizient

CUMBERLAND PHARMACEUTICALS RECEIVES VIZIENT CONTRACT FOR NEW VIBATIV® 4-VIAL STARTER PAK

Aug 4, 2025, 9:05 AM EDT - 1 year ago

CUMBERLAND PHARMACEUTICALS RECEIVES VIZIENT CONTRACT FOR NEW VIBATIV® 4-VIAL STARTER PAK

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q2 2025 FINANCIAL RESULTS & COMPANY UPDATE

Jul 29, 2025, 4:05 PM EDT - 1 year ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q2 2025 FINANCIAL RESULTS & COMPANY UPDATE

Cumberland shares latest results from its Phase 2 FIGHT DMD trial

2025-06-23T17:50:52.000Z - 1 year ago

Cumberland shares latest results from its Phase 2 FIGHT DMD trial

Cumberland Pharmaceuticals Shares Phase 2 FIGHT DMD Trial Results at the Parent Project Muscular Dystrophy Annual Conference

Jun 23, 2025, 9:05 AM EDT - 1 year ago

Cumberland Pharmaceuticals Shares Phase 2 FIGHT DMD Trial Results at the Parent Project Muscular Dystrophy Annual Conference

NEW STUDY FINDS CALDOLOR® SAFE AND EFFECTIVE FOR OPIOID-SPARING PAIN MANAGEMENT IN OLDER ADULTS

May 27, 2025, 4:05 PM EDT - 1 year ago

NEW STUDY FINDS CALDOLOR® SAFE AND EFFECTIVE FOR OPIOID-SPARING PAIN MANAGEMENT IN OLDER ADULTS

Cumberland announces partnership with Qureight

2025-05-13T20:22:40.000Z - 1 year ago

Cumberland announces partnership with Qureight

CUMBERLAND PHARMACEUTICALS PARTNERS WITH QUREIGHT TO ADVANCE INNOVATIVE IDIOPATHIC PULMONARY FIBROSIS TREATMENT RESEARCH

May 13, 2025, 4:05 PM EDT - 1 year ago

CUMBERLAND PHARMACEUTICALS PARTNERS WITH QUREIGHT TO ADVANCE INNOVATIVE IDIOPATHIC PULMONARY FIBROSIS TREATMENT RESEARCH

Cumberland Pharmaceuticals Earnings Call Transcript: Q1 2025

May 6, 2025, 4:30 PM EDT - 1 year ago

Cumberland Pharmaceuticals Earnings Call Transcript: Q1 2025

Cumberland Pharmaceuticals Quarterly report: Q1 2025

May 6, 2025, 4:30 PM EDT - 1 year ago

Cumberland Pharmaceuticals Quarterly report: Q1 2025

Cumberland Pharmaceuticals Earnings release: Q1 2025

May 6, 2025, 4:30 PM EDT - 1 year ago

Cumberland Pharmaceuticals Earnings release: Q1 2025

Cumberland Pharmaceuticals Reports 38% Revenue Growth in Q1 2025

May 6, 2025, 4:05 PM EDT - 1 year ago

Cumberland Pharmaceuticals Reports 38% Revenue Growth in Q1 2025

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q1 2025 FINANCIAL RESULTS & COMPANY UPDATE

Apr 29, 2025, 4:05 PM EDT - 1 year ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q1 2025 FINANCIAL RESULTS & COMPANY UPDATE

FIGHT DMD Trial Results Selected for Late-Breaking Presentation at MDA Clinical & Scientific Conference

Mar 19, 2025, 4:05 PM EDT - 1 year ago

FIGHT DMD Trial Results Selected for Late-Breaking Presentation at MDA Clinical & Scientific Conference

Cumberland Pharmaceuticals Proxy statement: Proxy Filing

Mar 10, 2025, 8:00 AM EDT - 1 year ago

Cumberland Pharmaceuticals Proxy statement: Proxy Filing

Cumberland Pharmaceuticals Proxy statement: Proxy Filing

Mar 10, 2025, 8:00 AM EDT - 1 year ago

Cumberland Pharmaceuticals Proxy statement: Proxy Filing

Cumberland Pharmaceuticals Earnings Call Transcript: Q4 2024

Mar 4, 2025, 4:30 PM EST - 1 year ago

Cumberland Pharmaceuticals Earnings Call Transcript: Q4 2024

Cumberland Pharmaceuticals Annual report: Q4 2024

Mar 4, 2025, 4:30 PM EST - 1 year ago

Cumberland Pharmaceuticals Annual report: Q4 2024

Cumberland Pharmaceuticals Earnings release: Q4 2024

Mar 4, 2025, 4:30 PM EST - 1 year ago

Cumberland Pharmaceuticals Earnings release: Q4 2024

Cumberland Pharmaceuticals Reports 11.6% Fourth Quarter 2024 Revenue Growth

Mar 4, 2025, 4:05 PM EST - 1 year ago

Cumberland Pharmaceuticals Reports 11.6% Fourth Quarter 2024 Revenue Growth

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2024 FINANCIAL RESULTS

Feb 25, 2025, 4:05 PM EST - 1 year ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2024 FINANCIAL RESULTS

VIBATIV® RECEIVES MARKETING APPROVAL IN CHINA

Feb 18, 2025, 7:30 AM EST - 1 year ago

VIBATIV® RECEIVES MARKETING APPROVAL IN CHINA

Cumberland Pharmaceuticals Announces Breakthrough Results from the Phase 2 FIGHT DMD Trial in Duchenne Muscular Dystrophy Heart Disease

Feb 4, 2025, 7:30 AM EST - 1 year ago

Cumberland Pharmaceuticals Announces Breakthrough Results from the Phase 2 FIGHT DMD Trial in Duchenne Muscular Dystrophy Heart Disease

FDA APPROVES ACETADOTE® sNDA

Dec 9, 2024, 4:05 PM EST - 1 year ago

FDA APPROVES ACETADOTE® sNDA

Cumberland Pharmaceuticals Earnings Call Transcript: Q3 2024

Nov 7, 2024, 4:30 PM EST - 1 year ago

Cumberland Pharmaceuticals Earnings Call Transcript: Q3 2024

Cumberland Pharmaceuticals Quarterly report: Q3 2024

Nov 7, 2024, 4:30 PM EST - 1 year ago

Cumberland Pharmaceuticals Quarterly report: Q3 2024

Cumberland Pharmaceuticals Earnings release: Q3 2024

Nov 7, 2024, 4:30 PM EST - 1 year ago

Cumberland Pharmaceuticals Earnings release: Q3 2024

Cumberland Pharmaceuticals Reports Third Quarter 2024 Financial Results and Company Update

Nov 7, 2024, 4:05 PM EST - 1 year ago

Cumberland Pharmaceuticals Reports Third Quarter 2024 Financial Results and Company Update

CUMBERLAND PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG AND RARE PEDIATRIC DISEASE DESIGNATIONS FOR NEW TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY

Nov 6, 2024, 5:21 PM EST - 1 year ago

CUMBERLAND PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG AND RARE PEDIATRIC DISEASE DESIGNATIONS FOR NEW TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY

TooHot_toTouch
TooHot_toTouch Aug. 4 at 6:34 PM
$CADL I think there are a few very good options for companies approaching the patent cliff. I would count all 3 in the mix to attract interests. $SLS $CPIX
2 · Reply
haha1978
haha1978 Aug. 4 at 5:29 PM
$CPIX could be any of these 3 companies. We don't really know.
0 · Reply
haha1978
haha1978 Aug. 4 at 5:21 PM
$CPIX and $CADL
1 · Reply
TwinTurboBul161
TwinTurboBul161 Aug. 4 at 3:51 PM
$XGN $CPIX Jet102
3 · Reply
KUMO2026
KUMO2026 Aug. 4 at 1:58 PM
$CPIX 8.06 test on the monthly
1 · Reply
KUMO2026
KUMO2026 Aug. 4 at 1:57 PM
$CPIX swing trade into break out
0 · Reply
TwinTurboBul161
TwinTurboBul161 Aug. 4 at 9:05 AM
$EZRA $GSUN $CPIX /watching3
0 · Reply
haha1978
haha1978 Aug. 4 at 5:09 AM
$CPIX tomorrow will be real interesting. Hoping the stock rerates on Wednesday to normal valuations a 300 million market cap so more institutions can start loading. This shpuld eventually be $20 minimum equal to capr at a minimum. They spiked to 700 plus million market cap on green light for AA on DMD cardiomyopathy by peter marks. So if cpic got a green light like capr on their p2. Boom probably 40 to 50 dollars a share by comparison. Its a great example of whst could happen.
0 · Reply
haha1978
haha1978 Aug. 4 at 2:38 AM
$CPIX still could be a cancer partnership soon.
0 · Reply
integrityfirst
integrityfirst Aug. 3 at 11:27 PM
$CPIX what matters right now, is the DMD extended study data. We hopefully will learn tomorrow when and how the data is to be delivered. Hopefully a Scientific conference or publication. If not that, there are other effective means of delivering. Ideally the company at least identifies date/context. Certainly tomorrow we should learn more of the current state of company post sale. We remain bullish on DMD as an indication. Further we are encouraged by the Phase 2A Cancer Metastatis trial data and think that this drug, in that indication, is already meaningfully partnered or sold. There is lots to discuss about this company's current state. Perhaps I will wait till after tomorrow's earnings call to opine/project. We are bullish.
0 · Reply
TwinTurboBul161
TwinTurboBul161 Aug. 3 at 10:24 PM
$CPIX Watchhlist
0 · Reply
Invest2live
Invest2live Aug. 3 at 8:57 PM
$CPIX 304% already; congrats 🔆🌿🌟 Checkout $HUMA and $AKBA excellent value now.
0 · Reply
Invest2live
Invest2live Aug. 3 at 8:56 PM
$CPIX
0 · Reply
Dogfon
Dogfon Aug. 3 at 7:22 PM
$CPIX this is the 5million dollar buy back..
2 · Reply
biotechdollars
biotechdollars Aug. 3 at 6:51 PM
$CPIX corporate update may include more than discussion of company financials post legacy asset sale. Have many hopes. Amongst them, it would be promising to hear of participation in the ESC August 28th, or a publication, in connection with DMD extended study results. This month's release is "almost" the entire ballgame. $CPIX
1 · Reply
vinland
vinland Aug. 3 at 6:04 PM
$CPIX all the way back, not too shabby. Congrats to those who held and collected the fat div to boot.
1 · Reply
peapope
peapope Aug. 3 at 3:10 PM
$CPIX DMD winner
0 · Reply
Dogfon
Dogfon Aug. 3 at 10:16 AM
$CPIX ifetroban will meet the needs of patients. An ACE inhibitor plus ifetroban is a winning combination for DMD cardiomyopathy. This is a no brainer. The study should be designed three arms placebo, ifetroban and ACE +ifetroban. Parents 125. This should slow Cardiomyopathy by 15% with combination treatment - reducing fibrosis significantly.
0 · Reply
haha1978
haha1978 Aug. 3 at 12:28 AM
$CPIX NASHVILLE, Tenn., July 28, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), an innovation-focused biopharmaceutical company committed to developing new products for rare diseases, announced today that it will provide a company update with second quarter 2026 financial results after the market closes on Tuesday, August 4, 2026.
0 · Reply
haha1978
haha1978 Aug. 3 at 12:08 AM
$CPIX https://finance.yahoo.com/healthcare/articles/cumberland-pharmaceuticals-announce-company-q2-200500445.html
0 · Reply
haha1978
haha1978 Aug. 1 at 11:14 PM
$CPIX got paid on the dividend today.
1 · Reply
UhtOh
UhtOh Jul. 31 at 8:02 PM
$CPIX Afterhours buy order in at $5.60 just in case dummies take control.
2 · Reply